Tenaris SA (TS) shares are outperforming the market today. The extra oomph comes via an upgrade from Goldman Sachs. Analyst, Henry Tarr lifted his recommendation to "Neutral" from "Sell."
Taking TS out of the penalty-box has the metal fabricator in the green by 1.53% as we type.
Based in Luxembourg with 26,825 employees, Tenaris is engaged in the steel pipe manufacturing and distribution activities. The company produces and sells seamless and welded steel tubular products, as well as provides related services for the oil and gas industry primarily oil country tubular goods used in drilling operations, and for other industrial applications.
[Related -Options Intelligence Report: Strangle Strategist Sees Sharp Shifts In Johnson Controls Shares]
It's sort of funny that Tarr would move off a rare "sell" recommendation with TS approaching its 52-week high of $49.87. This call at the end of March would have been spectacular, but it is easy to look backwards and criticize. The whole 20/20 vision thingy.
Best Internet Stocks To Buy For 2015: MGIC Investment Corp (MTG)
MGIC Investment Corporation (MGIC), incorporated June 21, 1984, is a holding company and through wholly owned subsidiaries is a private mortgage insurer in the United States. As of December 31, 2012, its principal mortgage insurance subsidiaries, Mortgage Guaranty Insurance Corporation (MGIC) and MGIC Indemnity Corporation (MIC), were each licensed in all 50 states of the United States, the District of Columbia and Puerto Rico. During the year ending December 31, 2012, the Company wrote new insurance in each of those jurisdictions in MGIC and/or MIC. The Company capitalized MIC to write new insurance in certain jurisdictions where MGIC no longer meets, and is unable to obtain a waiver of, those jurisdictions��minimum capital requirements. Private mortgage insurance covers losses from homeowner defaults on residential mortgage loans, reducing and, in some instances, eliminating the loss to the insured institution if the homeowner defaults.
Mortgage Insurance
Primary insurance provides mortgage default protection on individual loans and covers unpaid loan principal, delinquent interest and certain expenses associated with the default and subsequent foreclosure. Primary insurance is written on first mortgage loans secured by owner occupied single-family homes, which are one-to-four family homes and condominiums. Primary insurance is also written on first liens secured by non-owner occupied single-family homes, which are referred to in the home mortgage lending industry as investor loans, and on vacation or second homes. Primary coverage can be used on any type of residential mortgage loan instrument approved by the mortgage insurer.
When a borrower refinances a mortgage loan insured by the Company by paying it off in full with the proceeds of a new mortgage that is also insured by it, the insurance on that existing mortgage is cancelled, and insurance on the new mortgage is considered to be new primary insurance written. Therefore, continuation of its coverage fr! om a refinanced loan to a new loan results in both a cancellation of insurance and new insurance written. When a lender and borrower modify a loan rather than replace it with a new one, or enter into a new loan pursuant to a loan modification program, its insurance continues without being cancelled assuming that the Company consent to the modification or new loan.
The borrower�� mortgage loan instrument requires the borrower to pay the mortgage insurance premium. There are several payment plans available to the borrower, or lender, as the case may be. Under the monthly premium plan, the borrower or lender pays it a monthly premium payment to provide only one month of coverage. Under the annual premium plan, an annual premium is paid to it in advance, and it earns and recognizes the premium over the next 12 months of coverage, with annual renewal premiums paid in advance thereafter and earned over the subsequent 12 months of coverage. Under the single premium plan, the borrower or lender pays it a single payment covering a specified term exceeding twelve months.
Pool insurance is used as an additional credit enhancement for certain secondary market mortgage transactions. Pool insurance covers the excess of the loss on a defaulted mortgage loan which exceeds the claim payment under the primary coverage, if primary insurance is required on that mortgage loan, as well as the total loss on a defaulted mortgage loan which did not require primary insurance. Pool insurance is used as an additional credit enhancement for certain secondary market mortgage transactions. Pool insurance covers the excess of the loss on a defaulted mortgage loan, which exceeds the claim payment under the primary coverage, if primary insurance is required on that mortgage loan, as well as the total loss on a defaulted mortgage loan which did not require primary insurance. In general, the loans insured by it in Wall Street bulk transactions consisted of loans with reduced underwriting documentation; cash out! refinanc! es, which exceed the standard underwriting requirements of the Federal National Mortgage Association (Fannie Mae) and Federal Home Loan Mortgage Corporation (Freddie Mac) (collectively GSEs); A- loans; subprime loans, and jumbo loans.
Other Products and Services
The Company has participated in risk sharing arrangements with the GSEs and captive mortgage reinsurance arrangements with subsidiaries of certain mortgage lenders, which reinsure a portion of the risk on loans originated or serviced by the lenders, which have MGIC primary insurance. It provides information regarding captive mortgage reinsurance arrangements to the New York Department of Insurance (known as the New York Department of Financial Services), the Minnesota Department of Commerce and the Department of Housing and Urban Development, (HUD). It performs contract underwriting services for lenders, in which it judges whether the data relating to the borrower and the loan contained in the lender�� mortgage loan application file comply with the lender�� loan underwriting guidelines. It also provides an interface to submit data to the automated underwriting systems of the GSEs, which independently judge the data. These services are provided for loans, which require private mortgage insurance, as well as for loans that do not require private mortgage insurance. It provides mortgage services for the mortgage finance industry, such as portfolio retention and secondary marketing of mortgages.
The Company competes with Federal Housing Administration, Veterans Administration, PMI Mortgage Insurance Company, Genworth Mortgage Insurance Corporation, United Guaranty Residential Insurance Company, Radian Guaranty Inc., CMG Mortgage Insurance Company, and Essent Guaranty, Inc.
Advisors' Opinion:- [By Zachary Tracer]
Investors have poured cash into mortgage insurance this year as home prices rise, pushing up shares of MGIC Investment Corp. (MTG) and Radian Group Inc. (RDN) by more than 100 percent, and buying their notes in offerings. Essent Group Ltd. (ESNT), a mortgage guarantor funded amid the financial crisis by Goldman Sachs Group Inc. and billionaire George Soros, filed last month for an IPO. The companies cover losses when homeowners default and foreclosures fail to recoup costs.
- [By Garrett Cook]
In trading on Friday, financial shares were relative laggards, down on the day by about 0.40 percent. Top losers in the sector included MGIC Investment (NYSE: MTG), down 11.9 percent, and Radian Group (NYSE: RDN), off 5.2 percent.
- [By Wallace Witkowski]
Shares of private mortgage insurers fell after Radian Group Inc. (RDN) �called new proposed capital requirements ��nerous��but said it didn�� feel it would have to raise outside capital. Shares of Radian declined 3.8% to $14 on moderate volume, while shares of MGIC Investment Corp. (MTG) �fell 5.4% to $8.74 on moderate volume.
- [By Sean Williams]
What: Shares of MGIC Investment (NYSE: MTG ) , a mortgage insurance company to lenders and government-sponsored entities, jumped as much as 15% after handily topping Wall Street's earnings estimates in the second-quarter.
Top Up And Coming Stocks To Watch Right Now: Global X China Consumer ETF (CHIQ)
Global X China Consumer ETF (the Fund) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive China Consumer Index (the Underlying Index). The Underlying Index is a free float adjusted, liquidity tested and market capitalization-weighted index that is designed to measure performance of the investable universe of companies in the Consumer sector of the Chinese economy, as defined by Structured Solutions AG. Global X Management Company, LLC serves as the investment adviser to the Fund. Advisors' Opinion:- [By pamatlarge]
Investors looking to short a particular sector can choose from several Global X long ETFs. The Global X China Consumer ETF (CHIQ) concentrates its investments in consumer cyclical goods and consumer defense goods. The Global X China Energy ETF (CHIE) primarily holds stocks in coal, oil and utility companies. The Global X China Financials ETF (CHIX) only invests in financial services companies and real estate companies. The Global X China Industrials ETF (CHII) holds stocks in industrial companies and basic materials companies. The Global X China Materials ETF (CHIM) invests in basic materials stocks. The Global X China Technology ETF (CHIB) holds technology stocks as the core of its investments. All of these ETFs are particularly sensitive to sector downturns and general economic contractions.
Top Up And Coming Stocks To Watch Right Now: Coronado Biosciences Inc (CNDO)
Coronado Biosciences, Inc., incorporated on June 28, 2006, is a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer. The Company�� two principal pharmaceutical product candidates in clinical development include Trichuris suis ova or CNDO-201 (TSO) a biologic comprising of the microscopic eggs of the porcine whipworm, for the treatment of autoimmune diseases, such as Crohn�� disease (Crohn��), ulcerative colitis (UC) and multiple sclerosis (MS), and CNDO-109, a compound that activates natural killer (NK) cells of the immune system to seek and destroy cancer cells, for the treatment of acute myeloid leukemia (AML). In January 2011, the Company acquired the OvaMed GmbH License.
TSO
TSO is the microscopic eggs of a parasitic helminth, or worm, that is found in pigs. In September 2011, the Company filed an Investigational New Drug Application (IND) with the United States Food and Drug Administration (FDA) and it initiated a single dose, dose escalation study in patients with Crohn�� in February 2012. The Phase 1 clinical trial was a multi-center, sequential dose-escalation, double-blind, placebo-controlled study, the primary objective of which was to evaluate the safety and tolerability of TSO. The trial enrolled 36 patients with Crohn�� ranging in age from 20 to 54 with an equal distribution of male and female patients in three single dose cohorts of orally administered 500, 2500 and 7500 ova. Each cohort had 12 patients, with nine patients receiving TSO and three receiving placebo.
CNDO-109
CNDO-109 is a lysate (disrupted CTV-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor NK cells. CTV-1 is a leukemic cell line recently re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company has worldwide rights to develop and commercialize CNDO-109 activated NK cells for the treatment of cancer fro! m UCLB. In February 2012, the Company submitted an IND for the CNDO-109 activated NK cell product in the United States. The treatment of patients with CNDO-109 activated NK cells involves several steps. The activated NK cells are infused into the patient after resting NK cells are incubated with CNDO-109 for at least eight hours. Preparation of CNDO-109 activated NK cells takes about 24 hours from start to finish.
The Company competes with Centocor Ortho Biotech Inc.�� Remicade , UCB S.A.�� Cimzia, Abbott Laboratories��Humira, Biogen Idec�� Avonex, Bayer Healthcare Pharmaceuticals��Betaseron, Teva Pharmaceuticals Industries, Ltd.�� Copaxone and Novartis AG�� Gilenya.
Advisors' Opinion:- [By James E. Brumley]
The last few weeks haven't been particularly encouraging for Crohn's disease sufferers. In August, GlaxoSmithKline (NYSE: GSK) and ChemoCentryx (NASDAQ:CCXI) reported that a jointly-developed Crohn's drug, vercirnon, had failed to meet its late-stage trial endpoints. Though the in-development drug isn't dead in the water (GSK and CCXI could rework the drug, the testing regimen, or use it for other indications), it doesn't look good. Then this month - just a few days ago - Coronado Biosciences Inc. (NASDAQ:CNDO) reported that its Phase 3 trials of Crohn's disease drug TSO had also failed to meet its primary endpoints as well. Like vercirnon, CNDO isn't completely out of luck here with the treatment, but forging ahead with further development of the treatment is grasping at straws. Crohn's sufferers don't need to give up home just yet, however - TNI Biotech Inc. (OTCMKTS:TNIB) appears to have a Crohn's treatment that works, and should be able to sidestep the problems that plagued ChemoCentryx, GlaxoSmithKline, and Coronado Biosciences.
Top Up And Coming Stocks To Watch Right Now: Capital Bank Financial Corp (CBF)
Capital Bank Financial Corp, formerly North American Financial Holdings, Inc., incorporated in 2009, is a bank holding Company. The Company focuses on creating a regional banking franchise in the southeastern region of the United States through organic growth and acquisitions of other banks. As of March 31, 2011, the Bank operated 82 branches in Florida, North Carolina and South Carolina. On July 16, 2010, the Bank acquired approximately $1.2 billion of assets and assumed approximately $960.1 million of deposits of three banks from the federal deposit insurance corporation (FDIC): First National Bank of the South in Spartanburg, South Carolina, Metro Bank of Dade County in Miami, Florida and Turnberry Bank in Aventura, Florida. On September 30, 2010 and January 28, 2011, the Bank consummated controlling investments in TIB Financial and Capital Bank Corp., respectively. The Bank�� products and services included commercial bank business, consumer bank business, Mortgage Banking, and Private Banking, Trust and Investment Management. In October 2012, it acquired Southern Community Financial Corp.
Lending activities
As of March 31, 2011, the Bank�� loans included: Real estate mortgage loans, Commercial and agricultural loans and Home equity loans. Real estate mortgage loans include: Commercial, Residential, and Construction and vacant land. As of March 31, 2011, covered loans were $656.6 million, representing 22.3% of its loan portfolio. As of March 31, 2011, non-covered loans were $2.3 billion, representing 77.6% of its loan portfolio. As of March 31, 2011, loans related to real estate totaled $2.6 billion (or 87% of the Bank�� total loan portfolio). At March 31, 2011, commercial real estate loans in all regions totaled $1.8 billion.
Investment activities
Investment securities represent a major portion of the Bank�� assets. As of March 31, 2011, the Bank�� investment securities included mortgage backed securities, United States government agen! cies, states and political subdivisions, corporate bonds, equity, collateralized debt obligations and foreign government. Of the securities in the portfolio, 94% were rated AAA, and 97% were rated A or higher.
Sources of Funds
As of March 31, 2011, the Bank�� deposits included Non-interest demand deposit accounts, Interest Bearing demand deposit accounts, Savings and Money Market. It also included Customer Time Deposits and Wholesale Time Deposits. At March 31, 2011, total deposits were $3.5 billion of which $3.4 billion (or 97%) were non-brokered deposits and $94.4 million (or 3%) were brokered deposits. At March 31, 2011, the Bank�� core deposits (which are all deposits other than time deposits) consisted of $463.2 million of non-interest checking, $430.7 million of negotiable order of withdrawal accounts, $157.5 million of savings accounts and $456.2 million of money market deposits.
The Bank competes with Bank of America, Wells Fargo, BB&T, First Citizens, Royal Bank of Canada, SunTrust, Regions, FNB United Corp., Toronto-Dominion, Synovus, First Financial, SCBT, JPMorgan Chase, Citigroup, EverBank, Fifth Third Bancorp, First Horizon, Pinnacle Financial, First South and U.S. Bancorp.
Advisors' Opinion:- [By Tim Melvin]
The year ahead should be a great one for the smaller bank stocks. Larger regionals like Huntington Bancorp (HBAN) and Capital Ban Financial (CBF) have made it clear they intend to grow by acquisition in the years ahead. Banks like First Merit (FMER) and First Merchants (FRME) have done deals in the past year and are open to doing more to increase their market share and footprints. This should be the year the floodgates open and we see the first wave of merger activity in small banks.
Top Up And Coming Stocks To Watch Right Now: Trovagene Inc (TROV)
TrovaGene, Inc. (TrovaGene), incorporated on April 26, 2002, is a development-stage molecular diagnostic company that focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. The Company's novel tests predominantly use transrenal DNA (Tr-DNA) and transrenal RNA (Tr-RNA). The Company's technology is used to all transrenal nucleic acids (Tr-NA). The Company�� urine-based test addresses market needs, such as women�� healthcare-fetal medicine-down syndrome, infectious diseases, cancer testing, transplantation, drug development and monitoring of therapeutic outcomes, ultra-sensitive analytical and detection system, technologies for the collection, shipment and storage of urine specimens, and transrenal nucleic acid extraction, and instrumentation/system platform.
On January 18, 2011, the Company entered into an asset purchase agreement pursuant to which the Company acquired a hybridoma able to produce a monoclonal antibody targeting the NPM1 biomarker. On February 8, 2011, the Company entered into a sublicense agreement with MLL Munchner Leukamielabor (MLL). In July, 2011, the Company entered into a sublicense agreement with Fairview Health Services (Fairview) for NPM1 patent rights.
In October 2011, the Company entered into a license agreement pursuant to which the Company licensed the patent rights to a specific gene mutation with respect to chronic lymphoblastic leukemia. On December 12, 2011, the Company entered into a license agreement pursuant to which the Company licensed the patent rights to hairy cell leukemia biomarkers. On February 1, 2012, the Company acquired the clinical laboratory improvement amendments (CLIA) laboratory assets of MultiGEN Diagnostics, Inc. (MultiGEN).
Advisors' Opinion:- [By David Goodboy]
Fortunately, diagnostic issues may soon be a thing of the past. Several publicly traded companies are currently making great strides in the field of medical diagnostics, and my favorite company right now in that arena is TrovaGene (Nasdaq: TROV).
- [By Roberto Pedone]
TrovaGene (TROV) is a development stage molecular diagnostic company focused on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. This stock closed up 6% to $10.02 in Friday's trading session.
Friday's Volume: 712,000
Three-Month Average Volume: 183,106
Volume % Change: 294%From a technical perspective, TROV ripped higher here into all-time high territory with heavy upside volume. This stock has been uptrending strong for the last month and change, with shares soaring higher from its low of $5.75 to its new all-time high of $10.20. During that move, shares of TROV have been making mostly higher lows and higher highs, which is bullish technical price action. That move has also been accompanied by bullish upside volume flows.
Traders should now look for long-biased trades in TROV as long as it's trending above its recent breakout level of $8.83, and then once it sustains a move or close above its all-time high of $10.20 with volume that hits near or above 183,106 shares. If we get that move soon, then TROV will set up to enter new all-time high territory, which is bullish technical price action. Some possible upside targets off that move are $13 to $15.
- [By Daniel Lauchheimer]
In the past few weeks, I wrote two articles about TrovaGene (TROV) -- one detailing the history of the DNA market generally and the molecular diagnostics -- and TROV's place therein -- market specifically, and the second detailing the company's internal valuation. In this article, I will value TROV on an external, relative basis. Specifically, I will compare TROV to another molecular diagnostics company, Exact Sciences (EXAS), and try to show that while the market seems to have given EXAS a fair shake, it has not done the same for TROV. I will prove this argument by looking at both companies' addressable markets, and their respective progress at bringing the products to market. However, before we take this deep dive into both companies, I will take a moment to review each of the companies' products, so we have a strong background before turning to the deeper analysis.
Top Up And Coming Stocks To Watch Right Now: LKA Gold Inc (LKAI)
LKA Gold Inc, formerly LKA International, Inc., incorporated on March 16, 1988, owns certain property interests, including mining claims, water rights, buildings, fixtures, improvements, equipment, and permits situated near Lake City, Colorado. The Company�� the Lake City, Colorado Properties include the Ute-Ule silver mine and milling facility and the Golden Wonder gold mine (respectively, the Ute-Ule Property and the Golden Wonder Property or, collectively, the Properties). The Company owns a 100% interest in the Ute-Ule and Golden Wonder Properties. The Properties consist of certain mining claims and a milling facility located in Hinsdale County, Colorado. As of December 31, 2011, LKA was engaged in exploration and limited production at the Golden Wonder mine.
The Ute-Ule Property consists of 23 patented mining claims located approximately four miles west of Lake City, Colorado. A 100 ton-per-day flotation mill, including various equipment and support facilities, exists on the Ute-Ule Property. The Golden Wonder, near Lake City, Colorado, is located in the historic Colorado Mineral Belt.The Golden Wonder Property consists of three patented and 25 unpatented mining claims located approximately 2- 1/2 miles south of Lake City, Colorado.
Advisors' Opinion:- [By Peter Graham]
Small cap mining stocks US Tungsten Corp (OTCMKTS: USTU) and LKA Gold Inc (OTCMKTS: LKAI) along with biotech Entest BioMedical Inc (OTCMKTS: ENTB) have been getting some attention lately in various investment newsletters with at least one of these stocks being the subject of paid promotions while another could soon be the subject of an investor relations campaign. But will any of these small cap stocks be winners for investors or traders? Here is a quick reality check:
No comments:
Post a Comment